HAL (France)open access
The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?
Targeted therapies, 1, Co-mutations, 0, Non-small cell lung cancer, Immune checkpoint inhibitors, TP53, EGFR
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 215411
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.